Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
U.S. Veterans' Health Administration (VHA) Provides Coverage of LEQEMBI™ (lecanemab-irmb) for Veterans Living with Early Stages of Alzheimer's Disease
BioArctic AB’s partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing […]
BioArctic: Lecanemab Receives Priority Review Status in Japan
BioArctic AB’s partner Eisai has announced that the application for manufacturing and marketing approval for […]
Eisai Submits Marketing Application for lecanemab for Alzheimer's
BioArctic AB’s partner Eisai announced today that Eisai has submitted a marketing authorization application for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more